Takeda Pharmaceutical Company Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Julie So-Young Kim
- Full Time Employees
- 47,029
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1-1, Nihonbashi-Honcho 2-chome Tokyo OS Japan 103-8668
- IPO Date
- Jan 5, 2010
- CIK
- 0001395064
- Website
- takeda.com
- Similar Companies
- Business
- Takeda Pharmaceutical Company Limited operates globally, dedicated to the research, development, production, and commercialization of innovative biopharmaceutical treatments. The company focuses its scientific efforts and delivers therapies across several key areas: gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Its portfolio includes prominent brands such as Entyvio for inflammatory bowel diseases, Vyvanse for ADHD, and Takhzyro for rare genetic conditions, alongside various other products for oncology and plasma-derived needs. With operations spanning approximately 80 countries and regions worldwide, Takeda maintains a significant presence across Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific. The company actively engages in strategic alliances and licensing agreements to advance its pipeline and expand its market reach. Recent collaborations include a notable $11.4 billion deal with China's Innovent Biologics in October 2025 to accelerate immuno-oncology and antibody-drug conjugate cancer therapies. Additionally, Takeda expanded its partnership with Beacon Biosignals in November 2025 to further narcolepsy diagnosis and neurobiomarker discovery. The company also received FDA approval for Eohilia, an oral treatment for allergic inflammation of the esophagus, in February 2024. Founded in 1781, Takeda is headquartered in Tokyo, Japan, and remains a leading global biopharmaceutical firm driven by a patient-centric approach and commitment to sustainable healthcare solutions. It consistently invests substantially in research and development, with a robust late-stage pipeline aimed at delivering life-transforming medicines.
Company News
Critical Contrast: ProPhase Labs (NASDAQ:PRPH) & Takeda Pharmaceutical (NYSE:TAK)
Takeda Pharmaceutical (NYSE:TAK) vs. RYTHM (NASDAQ:RYM) Financial Survey
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Roche proposes former Takeda CEO for board seat
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Takeda Pharmaceutical (NYSE:TAK) versus Teva Pharmaceutical Industries (NYSE:TEVA) Financial Contrast
Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Best Value Stocks to Buy for September 14th
Best Income Stocks to Buy for September 14th
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Critical Survey: ABVC BioPharma (NASDAQ:ABVC) vs. Takeda Pharmaceutical (NYSE:TAK)
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera